Metformin therapy and risk of cancer in patients after heart
transplantation

J 2021

Metformin therapy and risk of cancer in patients after heart transplantation

BEDANOVA, H.; V. HORVATH; J. ONDRASEK; Jan KREJČÍ; Petr DOBŠÁK et al.

Základní údaje

Originální název

Metformin therapy and risk of cancer in patients after heart transplantation

Autoři

BEDANOVA, H.; V. HORVATH; J. ONDRASEK; Jan KREJČÍ; Petr DOBŠÁK a P. NEMEC

Vydání

Bratislava Medical Journal - Bratislavské lekárske listy, BRATISLAVA, Univerzita Komenského, 2021, 0006-9248

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30218 General and internal medicine

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.564

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/21:00124032

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

biguanide; heart graft; malignancy; diabetes mellitus; survival

Štítky

14110115, 14110118, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 2. 2. 2022 14:11, Mgr. Tereza Miškechová

Anotace

V originále

BACKGROUND: Diabetes mellitus (DM) and malignancy are recognized among the most common complications increasing mortality in patients after heart transplantation (HTx). Clinical trials have shown a higher risk for different types of tumours in diabetic patients. This risk is potentiated by immunosuppressive therapy in transplant patients. Biguanide metformin has been shown to exhibit anti-tumour activity and we tried to find out whether this effect is valid for heart transplant patients. METHODS: We retrospectively analysed a group of 497 patients, who undergone HTx in our centre between 1998 and 2019. The primary outcome was any malignancy during the 15-year follow-up period and patient's survival. RESULTS: Out of the 497 patients enrolled in the study, 279 (56 %) had diabetes and 52 (19 %) were treated with metformin. Fifteen-year survival in treated patients without malignancy was 93 %, the remainder for the DM patients was 56 %, with survival in non-DM patients being 74 %. Untreated diabetic patients had 4.7 times higher chance of malignancy than those on metformin (p = 0.01). Fifteen-year survival in metformin treated patients was 53 %, in other DM patients 44 %, and in non-DM patients 51 %. CONCLUSION: Our study showed a significantly lower incidence of malignancies in metformin-treated patients and slightly better overall survival (Tab. 2, Fig. 3, Ref. 19). Text in PDF www.elis.sk

Citovat

BEDANOVA, H.; V. HORVATH; J. ONDRASEK; Jan KREJČÍ; Petr DOBŠÁK a P. NEMEC. Metformin therapy and risk of cancer in patients after heart transplantation. Bratislava Medical Journal - Bratislavské lekárske listy. BRATISLAVA: Univerzita Komenského, 2021, roč. 122, č. 5, s. 305-309. ISSN 0006-9248. Dostupné z: https://doi.org/10.4149/BLL_2021_051.

@article{1830786,
   author = {Bedanova, H. and Horvath, V. and Ondrasek, J. and Krejčí, Jan and Dobšák, Petr and Nemec, P.},
   article_location = {BRATISLAVA},
   article_number = {5},
   doi = {https://doi.org/10.4149/BLL_2021_051},
   keywords = {biguanide; heart graft; malignancy; diabetes mellitus; survival},
   language = {eng},
   issn = {0006-9248},
   journal = {Bratislava Medical Journal - Bratislavské lekárske listy},
   title = {Metformin therapy and risk of cancer in patients after heart transplantation},
   url = {http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7195&category_id=171&option=com_virtuemart&vmcchk=1&Itemid=1},
   volume = {122},
   year = {2021}
}

TY  - JOUR
ID  - 1830786
AU  - Bedanova, H. - Horvath, V. - Ondrasek, J. - Krejčí, Jan - Dobšák, Petr - Nemec, P.
PY  - 2021
TI  - Metformin therapy and risk of cancer in patients after heart transplantation
JF  - Bratislava Medical Journal - Bratislavské lekárske listy
VL  - 122
IS  - 5
SP  - 305-309
EP  - 305-309
PB  - Univerzita Komenského
SN  - 00069248
KW  - biguanide
KW  - heart graft
KW  - malignancy
KW  - diabetes mellitus
KW  - survival
UR  - http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7195&category_id=171&option=com_virtuemart&vmcchk=1&Itemid=1
N2  - BACKGROUND: Diabetes mellitus (DM) and malignancy are recognized among the most common complications increasing mortality in patients after heart transplantation (HTx). Clinical trials have shown a higher risk for different types of tumours in diabetic patients. This risk is potentiated by immunosuppressive therapy in transplant patients. Biguanide metformin has been shown to exhibit anti-tumour activity and we tried to find out whether this effect is valid for heart transplant patients. METHODS: We retrospectively analysed a group of 497 patients, who undergone HTx in our centre between 1998 and 2019. The primary outcome was any malignancy during the 15-year follow-up period and patient's survival. RESULTS: Out of the 497 patients enrolled in the study, 279 (56 %) had diabetes and 52 (19 %) were treated with metformin. Fifteen-year survival in treated patients without malignancy was 93 %, the remainder for the DM patients was 56 %, with survival in non-DM patients being 74 %. Untreated diabetic patients had 4.7 times higher chance of malignancy than those on metformin (p = 0.01). Fifteen-year survival in metformin treated patients was 53 %, in other DM patients 44 %, and in non-DM patients 51 %. CONCLUSION: Our study showed a significantly lower incidence of malignancies in metformin-treated patients and slightly better overall survival (Tab. 2, Fig. 3, Ref. 19). Text in PDF www.elis.sk
ER  -

BEDANOVA, H.; V. HORVATH; J. ONDRASEK; Jan KREJČÍ; Petr DOBŠÁK a P. NEMEC. Metformin therapy and risk of cancer in patients after heart transplantation. \textit{Bratislava Medical Journal - Bratislavské lekárske listy}. BRATISLAVA: Univerzita Komenského, 2021, roč.~122, č.~5, s.~305-309. ISSN~0006-9248. Dostupné z: https://doi.org/10.4149/BLL\_{}2021\_{}051.

Přehled o publikaci